From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines

Nano-Micro Letters

Samson Afewerki¹  Joseph V. Bonventre²  Guillermo U. Ruiz-Esparza²  Xichi Wang³  Diana O. Lopez-Cantu⁴  Hector Carrasco-Magallanes⁵  Xingcai Zhang⁶ 

[1] Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 02115, Boston, MA, USA;Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, 02115, Boston, MA, USA;Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 02115, Boston, MA, USA;Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, 02115, Boston, MA, USA;Division of Renal Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 02115, Boston, MA, USA;Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 02115, Boston, MA, USA;Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, 02115, Boston, MA, USA;Division of Renal Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 02115, Boston, MA, USA;Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022, Wuhan, People’s Republic of China;Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 02115, Boston, MA, USA;Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, 02115, Boston, MA, USA;Division of Renal Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 02115, Boston, MA, USA;Tecnologico de Monterrey, School of Engineering and Sciences, 64849, Monterrey, NL, Mexico;Harvard T.H. Chan School of Public Health, 02115, Boston, MA, USA;Tecnologico de Monterrey, School of Medicine and Health Sciences, 64849, Monterrey, NL, Mexico;John A. Paulson School of Engineering and Applied Sciences, Harvard University, 02138, Cambridge, MA, USA;School of Engineering, Massachusetts Institute of Technology, 02139, Cambridge, MA, USA;

关键词: Nanovaccines;     mRNA;    Coronavirus;    SARS-CoV-2;    COVID-19;   

DOI  :  10.1007/s40820-021-00771-8

来源: Springer

【 摘 要 】

tsPfizer–BioNTech’s and Moderna’s nanotechnology-enabled mRNA vaccines are the first of its kind to be approved for human use.The COVID-19 pandemic has changed our lives and although SARS-CoV-2 has caused irreversible health, social and economic damage, continuous and extensive efforts world-wide were essential to reduce its deleterious effects.

【 授权许可】

CC BY